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Abstract
Human Interlekin-17 is produced by memory activated CD4+ T cells and other
cells. It was initially considered unique in that its specific receptor is distinct from
other cytokine receptors. IL-17 receptor is ubiquitously expressed by different cells
including T cells. IL-17 plays a role in regulating growth, immune response and pro-
inflammatory responses. It regulates differentiation of a subset of Th0 cells into Th-
17 cells, which produce IL-17-induced cytokines. The IL-17R belongs to type 1
cytokine receptors. IL-17 belongs to a superfamily of its own, which includes
IL-17A, IL-17B, IL-17C, IL-17E and IL-17F. These members of IL-17 superfamily
have some sequence homology but bind to different receptors. Prior to this investi-
gation, limited information existed on the effects of IL-17A in human leukemia cell
lines. Our results show that IL-17A promotes growth, anti-apoptotic effects, che-
motaxis, cytokine expression and transcriptional factor activation in leukemia cells.
IL-17A activates multiple signaling pathways including PI-3 K, Jak–STAT, Raf-
ERK1/2 and SRC kinase pathways, which mediate different biological effects of
IL-17A in leukemia cells. Our findings implicate IL-17A in leukemia cell growth and
survival, supporting potential leukemia therapy via development of anti-IL-17A
drugs. This chapter focuses on IL-17A, herein referred to as IL-17.
Keywords: IL-17A, leukemia, cytokines, Jak/STAT, PI-3 K/Akt,
ERK1/2 transcriptional factors
1. Introduction
IL-17 is a unique cytokine which was initially discovered through differential
and subtractive screening of clones from DNA library from murine lymphoid cells
and initially called T-lymphocyte associated antigen 8 (CTLA-8) [1]. IL-17 was
found to have 50% sequence homology to the open reading frame 13 (ORF-13) in
herpes virus Saimiri [1]. Subsequently, the human homolog of CTLA-8 was identi-
fied [1] and its incubation with human fibroblast resulted in induction of both IL-6
and IL-8. This led to renaming of the CTLA-8 human equivalent as IL-17 [2].
Human IL-17 production was also found to be limited to particular cellular elements
of the immune system and that activated CD4 + T cells of the Th1/Th0 subset and
1
stimulated memory T cells, synthesize IL-17 [3, 4]. IL-17 is a glycosylated
homodimeric protein of 30 to 35 kDa also produced by nickel-specific T lympho-
cytes and it regulates I-CAM-1 expression and chemokine production [5]. Unlike
other cytokines, IL-17 was noted to bind to a unique receptor distinct from other
cytokine receptors [1–3]. IL-17 is ubiquitously expressed in thymocytes activated by
CD3 mAb, CD45R0+ population of T cells, CD8+ splenic cells in mouse cells and
synovial fluid of patients with rheumatoid arthritis [6–8]. IL-17 is abundantly pro-
duced in CD4+ T cells, now known as Th-17 cells [9–11]. It is also expressed in
human peripheral blood mononuclear cells (PBMC) in response to ocular lysate in
patients with birdshot chroioretinopathy [12]. IL-17 has biological effects in many
cells and tissues [13–15]. IL-17 induces expression and secretion of IL-1-beta, IL-6,
IL-8. TNF, GM-CSF, G-CSF, ICAM-1, and PGE2 [16–20]. The molecular character-
ization of IL-17 receptor (IL-17R) was reported in 1997 [21]. IL-17R is a type 1
transmembrane receptor and it is a single chain, which shares some properties with
IL-2R-beta chain, and GM-CSFR, all of which are type 1 membrane receptors
[21, 22]. IL-17R is also expressed in synovial endothelial cells and Chondrocytes
from arthritis patients [23, 24].
Five different IL-17 ligands are now characterized as members of IL-17 super-
family of cytokines and differ from other cytokines but share some sequence
homology with each other [25]. Among the IL-17 super family, IL-17A is most
commonly expressed in many tissues as well as in cells of hematopoietic origin
including monocytes and macrophages. In addition to IL-17A, there are IL-17B,
IL-17C, IL-17E and IL-17F [25, 26]. IL-17B, IL-17C and IL-17E expression are wide-
spread in many tissues including testis, brain and kidney [25, 26]. Each IL-17 family
members have their individual specific receptor as these IL-17 family members do
not bind to the same receptor type [26–28]. The different members of IL-17 super-
family have different expression patterns but with similar abilities to stimulate
cytokine effectors illustrating the potential for the members of the IL-17 superfam-
ily to differentially regulate cellular responses in a wide variety of cells [28–31].
IL-17 regulates hematopoietic cell proliferation, immune response, pro-
inflammatory responses [32–35] and activate specific types of T cells now known as
Th-17 cells [9, 10]. These Th-17 cells play a role in host defense against extracellular
pathogens by mediating recruitment of neutrophils and macrophages to infected
tissues [9–11]. Th-17 cells secrete IL-17 cytokines, which in turn induce expression
of IL-17-depedemt cytokines. Hence, aberrant regulation of Th-17 cells may play a
role in the pathogenesis of multiple inflammatory and autoimmune disorders
[9–11]. IL-17 promotes chemotaxis in human monocytes and regulates angiogenesis
and cytokine production in endothelial cells [12, 36–38]. Although the target cells of
IL-17-mediated signaling include immune cells such as neutrophils and macro-
phages [32–38], majority of IL-17’s biological effects were seen in cells of either
epithelial or mesenchymal origin [39–43]. The role of IL-17 in immunological func-
tion was initially examined in vivo in mice by overexpressing IL-17 in the liver of
mice where an enhanced granulopoiesis and leukopoiesis led to an 80% increase in
splenic mass [38, 39]. IL-17-induced accumulation of neutrophils in the airways
requires involvement of GM-CSF [44]. Also, regulation of endogenous stem cell by
IL-17 requires both GM-CSF and Stem Cell Factor (SCF) [45]. IL-17 and G-CSF are
synergistically involved in the maintenance of normal granulopoiesis [45]. The
IL-17R is ubiquitously expressed [12–15] and may explain the ability of IL-17 to
stimulate peripheral blood stem cells in in mice [44, 45]. Also, There IL-17 plays
active in vivo role in chemoattraction of cells of immune system [46, 47]. In
addition, IL-17 exhibits paracrine effects in different cell types [48] whereby
secreted IL-17 from T cells binds to its putative receptor on neighboring cells such as
fibroblasts and trigger signaling that leads to NF-kB- mediated induction of
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expression and secretion of ICAM-I, IL-2, IL-6, IL-8 [16–20] and other cytokines,
which produce different biological effects [45–50]. Also some of the T-cell secreted
IL-17 become sequestered and neutralized by a soluble IL-17R (sIL-17R) [51].
Clinically, IL-17 is implicated in numerous diseases including arthritis [52–54],
classical Hodgkin lymphomas [55–57], multiple myeloma [58–60], airway diseases
including asthma [61, 62], musculoskeletal diseases [63, 64], inflammatory bowel
diseases (IBDs) [65] autoimmune diseases [66], and different types of cancer
[67–69]. Significantly elevated level of IL-17 and IL-17R are found in these diseases
and IL-17 and IL-17R are known to promote anti-apoptotic effects and survival
mechanisms in some types of cancer [55–66]. In most cases, IL-17 itself and/or IL-17-
dependent cytokines produced downstream of the IL-17R, contribute to various
pathological conditions associated with these diseases [55–68]. Furthermore, Hox3/
IL-17R expression ratio has been implicated in poor prognosis in some breast cancer
patients undergoing tamoxifen chemotherapy as IL-17 promotes resistance to che-
motherapy in breast cancer [67–71]. IL-17 is also implicated in cervical and ovarian
cancer [72–74]. Similarly, expression of IL-17 R-like protein has been detected in
androgen independent prostate cancer cell lines and it has been implicated in confer-
ring resistance to apoptosis and promoting prostate cancer via MM7-induced
epithelial-to-mesenchymal transition [75–77]. IL-17 is implicated in CNS and other
neurological diseases [78–80], and psoriasis [81–83]. Recent reports suggest potential
role for IL-17 in the “cytokine storm event” seen in advance Coronavirus Disease
2019 (COVID-19) infection with inflammation, and pro-thrombic events in severe
COVID-19 patients [84–87]. Hence, there is strong interests in understanding IL-17’s
biology and it roles in COVID-19 patients [85–87]. It is not surprising that IL-17’s role
in these diseases [60–87], have prompted experts in pharmaceutical industries to
develop anti-IL-17 type therapies for diseases in which IL-17 is implicated [88–90].
Earliest report on IL-17 induced activation of MAP kinases and NF-kB pathways
was made in chondrocytes [91]. Subsequently, IL-17 was shown to activate Raf-
MAPK and Jak/STAT signaling pathways in leukemia cells [92, 93]. These reports
show that IL-17 stimulates rapid phosphorylation of RAF, Erk-1/2, Jak1, Jak2, Jak3 and
Stat1, Stat2 and Stat3 in human leukemia cells [92, 93]. Currently, IL-17 is known to
activate and utilize multiple signaling pathways including the aforementioned as well
as JNK, p38 and PI-3 K/Akt pathways to produce diverse biological effects [91–96].
Many reports have confirmed IL-17-induced activation of PI-3 K/Akt signaling
mechanisms in both normal and transformed cells [96–99]. IL-17 signaling pathways
are implicated in human diseases including inflammation and cancer [100]. Further-
more, TRAF and TGF-beta-1/smad2/3 signaling pathways are activated by IL-17 [99–
102]. Most of the biological effects of IL-17 were initially observed in different variety
of cells but to lesser extent in leukemia cells. Therefore, our rationale for initiating this
study was to determine the biological effects of IL-17 in leukemia cells and elucidate
the various signaling pathways utilized by IL-17 in leukemia cells. Furthermore, we
wanted to determine which transcriptional factors are activated by IL-17. Finally, we
wanted to determine whether IL-17 protects leukemia cells from undergoing apoptosis
since previous report [75] indicated IL-17mediates cancer cell resistance to apoptosis.
2. Experiment reagents and protocols
We purchased human U937 and THP-1 leukemia cell lines from American Tissue
Culture Collection (ATCC) in Manassas, VA, USA. The cells were cultured in
Roswell Park Memorial Institute-1640 media, which contained L-Glut (2 mM).
Charcoal-filtered and frozen fetal bovine serum (FBS) was purchased from Atlanta
Biological, Georgia, USA. Following careful thawing under sterile conditions we
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heated the serum at 55 °C for 45 minutes for inactivation. After cooling, we vacuum
filtered the FBS under the hood and stored 50 ml aliquots at minus 20 °C. Both
streptomycin and penicillin were purchased from Invitrogen, Carlsbad, CA. Prior to
using the culture media, we added FBS to a final concentration of 10% (v/v). To
prevent bacterial growth in the culture media, we added penicillin (50 U/ml) and
streptomycin (50 U/ml). We cultured the cells in either 25 ml or 50 ml of complete
media in tissue culture flasks in a CO2 incubator set to 5% CO2, 37 °C and 100%
humidity. Typically, we passaged the cells 8x before starting a fresh culture. U937
leukemia cells were used in most of the experiments described here.
2.1 Monocyte isolation
We purchased de-identified human blood samples from New York Blood Cen-
ter, Long Island, NY and Percoll gradients from GR Health Care, Piscataway, NJ
[103]. To isolate monocytes for chemotaxis assays, we isolated peripheral blood
mononuclear cells (PBMC) as previously described [103]. After centrifugation to
remove all red blood cells, the white blood cells were carefully retrieved and
suspended in 10 ml of complete media and spread across the surface of plastic
dishes. The plastic dishes were incubated in the incubator for 1.5 hours to allow
monocytes to attach to the surface of the dishes. Subsequently, all non-adherent
cells were carefully aspirated off and discarded. The attached monocytes were
carefully scraped from the dishes and suspended in culture media. The monocytes
were about 95% pure based on positive staining for CD14 marker.
2.2 Detection of cytokine expression by cytokine antibody array
To determine the effect of IL-17 on cytokine expression in leukemia cells, we
performed cytokine antibody array using tissue media from untreated and IL-17
treated leukemia cells [103]. Specifically, 20million cells were either untreated or
treated with IL-17 (100 ng/ml) alone or with IL-17 (100 ng/ml) plus the PI-3 K
inhibitor LY20094 (20 uM) or with LY20094 (20 uM) alone for 24 hours. The
tissue culture media were filtered to remove debris and their protein concentration
determined by Coomassie Blue Protein Assay Kit (Pierce, IL). The culture media
containing 50 ug protein from untreated and treated cells were spotted onto each of
the cytokine/antibody array membranes containing antibodies for over 42 cytokines
(RayBiotech, Corners, GA, USA), and incubated with gentle shaking for 2 hours at
30 °C. This allowed hybridization of each cytokine in the media to its respective
cytokine antibody on the array. Next, the media was carefully removed and each
membrane was washed 5x with wash buffer (provided by kit) to remove all non-
specific binding. Each membrane was incubated for a specified time in the color
development solution provided with kit and air dried. The dark spots representing
various cytokines were visualized and quantitated by digital image scanning. The
spot intensities were converted to fold change relative to the corresponding spots on
the membrane of the untreated cells, which was set as 1-fold.
2.3 Western blotting detection of proteins and phosphoproteins
One million leukemia cells per ml media were either untreated (control) or
treated with [92, 93] IL-17 (1 ng/ml) for 2, 5, 15, 30, 60 min or with IL-17 (100 ng/
ml) at 30 °C treatments up to 48 hours. Next, the cells were rapidly pelleted by
micro-centrifugation at 1,800 x g for 3 minutes. The pelleted cells were washed 3x
with PBS. The final pellets were collected by centrifugation at 1800 rpm for 3 min
and each pellet was lysed in 500 ul of cell lysis buffer A (containing protease
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inhibitors, 0.5% Triton X-100, 50 mM NaF and 2 mM Vanadate) [7]. Total cell
lysate protein concentration was determined by Coomassie Blue Protein Assay Kit
(Pierce, IL) and 240 ug per sample was solubilized in 50 ul SDS gel sample buffer
and resolved by 12% polyacrylamide gel electrophoresis. The protein bands were
transferred to membrane and the membrane background blocked in a blocking
buffer containing 5% milk. The membranes were incubated with specific antibodies
to either total PI-3 K, p-PI-3 K, p-AktSer473, p-AktThre308, total Akt, p-STAT3, total
STAT3, p-BAD, p-caspase3 or pGSK3-beta or total actin (for loading control) and
protein bands detected [103]. The band intensities were scanned by digital image
analyzer for quantitation and the band intensity from IL-17 treated samples com-
pared to the intensity in the untreated sample.
2.4 Co-immunoprecipitation (co-IP) assay/Western blot
Total and phosphorylated Akt can associate with effector proteins [104, 105] via
protein–protein interaction [106] and contribute to their regulation. We rationalized
that if IL-17 promotes association between p-Akt and any of its downstream effec-
tors, those proteins will be contained in the pulled down p-Akt-antibody complex and
can be detected by co-IP/Western blot. To determine whether Akt/p-Akt binds to p-
BAD or p-Caspase3 or p-GSK-3 (p-Akt’s downstream effectors), we carried out co-IP.
Specifically, 240 mg/ml protein from untreated or IL-17 treated cells were suspended
in PBS (500 ul) in Eppendorf tubes and incubated with specific antibody that recog-
nizes both total Akt and p-AktSer473 overnight with gentle shaking at 4 °C. Next,
protein A agarose slurry (500 ul) was added to the complex in each tube and incu-
bated for 2 hours at 4 °C with gentle shaking to allow protein A agarose to capture all
the phosphoproteins bound to Akt/p-Akt-antibody complex. The tubes were
centrifuged at 10,000 x g for 10 minutes at 4 °C, the supernatants carefully removed
and the pellets were washed 5x with lysis buffer (see above). After the final wash, the
phosphoprotein complexes in each tube was solubilized in SDS-gel sample buffer (50
ul) and boiled for 3 minutes to dissociate the phosphoproteins in each complex. The
dissociated phosphoproteins were separated on 12% SDS-polyacrylamide gel as
described above. The phosphoprotein bands were transferred to membrane and
Western blotted for either p-BAD or p-Caspase3 p-GSK-3 or total Akt using specific
antibodies. The band intensity for p-BAD, p-Caspase3 and p-GSK-3 were scanned
with digital image analyzer. The old levels in the IL-17 treated cells calculated relative
to the bands in the untreated cells. Representative results are presented.
2.5 Detection of IL-17RA in U937 leukemia cells and THP-1 leukemia cells
Specific antibody to IL-17AR was purchased from Santa Cruz, CA and goat anti-
rabbit IgG-HRP antibody was from Amersham, CA. In order to detect IL-17AR, 240
ug of total cell lysate protein from 40 million cells was separated on 15% polyacryl-
amide gel [106]. The protein bands were transferred to nitrocellulose membrane
followed by incubation in a blocking buffer containing 5% filtered non-fat milk to
block non-specific sites on the membrane. Both the IL-17AR antibody and the goat-
anti-rabbit antibody were used at dilutions of 1:1000. The rest of the Western blot
protocols were performed as described [103, 106]. The band intensity was quanti-
tated using digital image analyzer.
2.6 Transcription factor array
To detect transcriptional factors regulated by IL-17 stimulation in leukemia cells,
we examined the profile of 54 transcriptional factors (TFs) using Panomics
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Transcriptional Factor Array (1) Kit. Panomics TranSignal™ Protein/DNA Arrays
simplifies the functional analysis of eukaryotic TFs and can be used to study TF
activation in a variety of biological processes, including cell proliferation, differen-
tiation, transformation, apoptosis and drug treatment [107]. The array membranes
were spotted with 54 different consensus-binding sequences (oligos) and enable
one to detect over 54 TFs at once in one treatment. Twenty million leukemia cells/
ml were pretreated with vanadate (5 mM) for 30 minutes to inhibit endogenous
phosphatases. Next, 5 million of the cells we either untreated or stimulated with
IL-17 (100 ng/ml) for 4 hours in the incubator. The cells were packed by centrifu-
gation at 1,800 x g for 3 minutes, washed 3x with PBS and gently lysed in a lysing
buffer (see Western blot protocols above) without detergents by repeated aspira-
tion through a 22-gauge needle to prevent rupturing of the nuclei. Intact nuclei were
isolated by layering the cell lysate over 50% glycerol solution in Eppendorf tubes
followed by centrifugation at 1,000 x g for 5 minutes. The supernatants were
carefully aspirated, the nuclei pellet harvested and washed 2x with PBS. Next, the
nuclei were disrupted in a nuclei lysing buffer (provided by the kit) and protein
concentration determined as described above. In a slightly modified version, 12 ug
of nuclei proteins in 200 ul of incubation buffer were incubated with each array
membrane containing the oligos for hybridization of each oligo to its specific tran-
scriptional factor in the nuclei extract. The membranes were washed several times
and the oligo/transcriptional factor complexes (DNA/protein complexes) were
detected by detection per the kit. The spots representing the various transcription
factors were identified based on the charts provided by the kit. The intensities of the
spots were scanned by digital image analyzer and the fold stimulation by IL-17
compared to the intensities in the untreated cells.
2.7 NF-kB/DNA and STAT3/DNA binding assays for detection of NF-kB and
STAT3 activation by IL-17
To study the effect of IL-17 on NF-kB and STAT3 DNA binding functions
[108, 109], 4 million leukemia cells/ml were untreated or IL-17 in time course
experiments. The cells were used for specific NF-kB/DNA binding or STAT3/DNA
binding assays using the NF-kB and STAT transcription factor assay kits (Active
Motif, Chemicon). The kit enabled us to monitor the activation or repression of
NF-kB or STAT3 proteins. The experiments were performed in triplicate.
2.8 Cell proliferation assays
To determine whether IL-17 stimulates cell proliferation in leukemia cells, 6 x
105 cells were either untreated or stimulated with IL-17 (100 ng/ml) for 48 hours
[110]. The cells were harvested and aliquots were diluted into 0.4% trypan blue/
PBS solution at a ratio of 1:10. The cells were counted in triplicate and the average
viable cell count was recorded from each sample. We also performed MTT prolif-
eration assay using 4 x 105 cells untreated or cells treated with IL-17 (100 ug/ml) for
48 hours in 96 well plates in triplicate. The rest of the details of the MTT assay
protocols were as previously described [110].
2.9 Caspase3 activity assays as evidence for apoptosis
We purchased caspase3 assay kit from MBL International, Woburn, MA, US
[111]. Sodium butyrate (NaB) is a strong inducer of apoptosis in cancer cells [112].
To determine the effects of IL-17 on NaB-induced apoptosis in leukemia cells we
performed caspases3 enzymatic (colorimetric) assays in lysates from 15 x 106
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untreated or NaB treated cells. Specifically, the cells were either untreated or
treated with NaB (5 mM) alone, or treated with NaB (5 mM) plus IL-17 (100 ng/ml)
or with IL-17 (100 ng/ml) alone in tissue culture media for up to 48 hours. At the
end of the incubation, aliquot of cells were counted prior to lysing in RIPA buffer
(provided in the caspase3 assay kit) and total lysate protein concentration was
determined as indicated above. To measure caspase3 activity in the cell lysates, 30
ug total lysate protein from each sample was added to each experimental assay well.
The enzymatic activity was measured in triplicate in microtiter plate reader
according to instructions provided by the kit.
2.10 Assessment of chemotactic effects of media from IL-17 treated cells
In order to ascertain if media from IL-17 treated cells has chemotactic effects
towards monocytes [103, 113], we employed the Boden Chamber chemotaxis assay
method as previously described [103]. Specifically, 2000 monocytes/ml in fresh
complete media were placed in the upper portion of the Boden Chamber. Equal
volume of media from either untreated or IL-17 stimulated cells was put in the
lower chamber to serve as a source of chemotaxis. The setup was incubated for 2-
hours. Next, estimation of number of monocytes which crossed the membrane
barrier to the lower chamber was performed according to the kit. Experiments were
conducted in triplicate.
2.11 Assessing IL-17-induced cytokine expression by cytokine ELISA
In order to validate IL-17-induced cytokine expression observed in the cytokine
antibody array, we performed cytokine ELISA assay as specified in the cytokine
ELISA Kits (Ray Biotech, Norcross, GA) using equal amount of tissue culture pro-
teins from untreated or IL-17 treated cells [103]. The ELISA monitored expression
of IL-2, IL-3 and IL-8. In addition, to determine whether IL-17-induced IL-2
expression was mediated by either PI-3 K/Akt or by Jak2, in some experiments, we
pre-incubated some of the cells with PI-3 K inhibitor LY20094 (20 nM) or Jak2
inhibitor AG490 (15 nM) for 30 minutes prior to stimulating the cells with IL-17
(100 ng/ml) for 24 hours.
3. Results
3.1 Effects of IL-17 on cytokine expression in human leukemia cells
To determine whether IL-17 stimulates cytokine expression in leukemia cells, we
performed cytokine antibody array using tissue culture media from untreated and
treated cell. As seen in Figure 1, within 24 hours IL-17 stimulated several fold
differential expression of various cytokines in the ranking order of IL-2 > IL-
3 > GRO > IL-10 > RANTES>IL-15 > IL-1. However, IL-17 failed to simulate IL-8
expression. Stimulation of cytokine expression by IL-17 was significantly inhibited
by the PI-3 K inhibitor LY20094 (Figure 1), suggesting a role for PI-3 K in the
mechanism by which IL-17 stimulates cytokine expression. Similar results were
observed in THP-1 human leukemia cell line (data not shown). Also, a neutralizing
antibody against of IL-17 blocked IL-17 from stimulating cytokine expression (data
not shown), confirming that the observed stimulation of cytokine expression is
attributed to L-17. Using ELISA assay, we confirmed stimulation of IL-2 and IL-3
expression by IL-17 without effect on IL-8 expression (Figure 2). The lack of effect
of IL-17 on IL-8 expression seen in leukemia cells are in contrast to IL-17-induced
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IL-8 expression reported in different cell types [16–20]. As a follow up to our results
in Figure 1, and our previous report that IL-17 activates Jak/STAT pathway [93], we
determined whether both the PI-3 K and Jak2 mediate stimulation of specific cyto-
kine expression by IL-17. To do so, we examined the effects of PI-3 K inhibitors
LY20094 (LY) and wortmannin (WM) and Jak2 inhibitor AG490 (AG)) on IL-17-
induced IL-2 expression. The ELISA array results in Figure 3 indicate that individ-
ually LY20094 and wortmannin partially inhibited IL-17 stimulated IL-2 expression.
The Jak2 inhibitor AG490 also exhibited similar inhibitory effect on ability of IL-17
to stimulate IL-2 expression. A combination of both LY20094 and AG490
completely blocked stimulation of IL-2 expression by IL-17 (not shown). These
results confirmed roles for both PI-3 K and Jak2 in the mechanisms by which IL-17
stimulates IL-2 expression.
3.2 Media from IL-17 treated leukemia cells produce chemotaxis
Given that IL-17 stimulated significant expression of two chemokines (GRO and
RANTES), we examined whether the culture media from IL-17 treated leukemia
cells could serve as chemoattractant to human monocytes from PBMC. As seen in
Figure 1.
IL-17 Stimulation of differential expression of cytokines: Inhibition by PI-3K Inhibitor (LY20094). Tissue
culture media from untreated and treated cells were assayed for cytokine expression by cytokine-antibody array.
Data is an average of two experiments.
Figure 2.
Effects of IL-17 on IL-2, IL-3 and IL-8 expression. Asterisk (*) indicates significant differences between IL-17
treated and untreated cells.
8
Interleukin
Figure 4, as compared to culture media from untreated cells, culture media from
IL-17 treated cells exhibited significant time-dependent chemotaxis towards
monocytes, confirming that culture media from IL-17 treated cells contains secreted
chemotactic chemokines that induced chemotaxis [46].
3.3 IL-17 stimulates leukemia cell growth and protection from apoptosis
Next, we investigated the effect of IL-17 on leukemia cell proliferation.
Untreated or IL-17 stimulated cells were assessed for cell growth using trypan blue
exclusion and MTT assays. As shown in Table 1, IL-17 exhibited a time-dependent
stimulation of leukemia cell growth by 3.3-fold within 48 hours. Similar results
were seen in MMT assays (data not shown). Next, we examined whether IL-17
promotes leukemia cell survival and anti-apoptotic effects in leukemia cells by
protecting the leukemia cells from apoptosis. The results in Table 2 indicates that
NaB alone causes significant reduction in leukemia cell survival from 100% to 52%
in 24 hours. However, in the presence of IL-17, Na-induced decline in cell survival is
Figure 3.
Inhibition of IL-17-induced IL-2 expression by PI-3K inhibitors (LY and WM) and Jak2 inhibitor (AG).
Asterisk (*) indicates significant differences between IL-17 alone and IL-17 plus PI-3K Inhibitors (LY and
WM) or Jak2 inhibitor (AG490).
Figure 4.
IL-17 induced Chemotaxis. Tissue culture media from untreated IL-17 cells were assayed for chemotaxis in a
Boyden Chamber with monocytes on the upper chamber.
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markedly inhibited cell survival improved from 52% to 83%. As shown in Table 3,
NaB alone stimulated activation of caspase3 activity from 1-fold in untreated cells
to 3.2 fold in 24 hours and 4.3-fold in 48 hours, indicating NaB-induced apoptosis in
cells in the absence of IL-17. However, in the presence of IL-17, NaB-induced
caspase3 activation is markedly reduced from 3.2-fold to 1.7-fold in 24 hours and
from 4.3-fold to 2.0-fold in 48 hours. IL-17 also upgrades Bcl2 in the presence of
NaB (not shown). Thus, IL-17 protects leukemia cells from undergoing apoptosis
and enhances their survival. The results suggest that IL-17 may be inducing
inactivation of pro-apoptotic signals while partially restoring the anti-apoptotic
protein Bcl-2 expression.
3.4 IL-17 stimulates differential activation of transcription factors in
leukemia cells
Within 4 hours IL-17 stimulated significant and differential activation of several
transcription factors in the order of c-Myb (5.5-fold) > EGR-1 (5.0-fold) > STAT3
(4.0-fold)> > Smad3/4 (3.4-fold) > SRE (3.0 fold>CDP (2.5-.fold). IL-17 failed to
activate NF-kB. Using individual transcription factor/DNA binding assays, we
confirmed that STAT3/DNA binding activity is significantly enhanced by IL-17
(Figure 5). In contrast, IL-17 did not stimulate NF-kB/DNA binding activity in
these leukemia cells (Figure 6). Together these results show that IL-17 differentially
activates several transcriptional factors associated with regulation of cell growth,
cell differentiation and apoptosis but failed to stimulate NF-kB in these cells even
though IL-17 is known to stimulate NF-kB in many cell types [50]. Of note, NF-kB
Treatment 24 hours Cell Growth (Fold) 48 hours Cell Growth (Fold)
Cells 1.0 1.0
Cells + IL-17 2.3.0 3.3  0.2
Table 1.
Effects of IL-17 on cell growth, cell survival and caspase3 activity—IL-17 promotes cell growth.
Treatment 24 hours Cell Survival (%)
Cells alone 100
Cells + NaB 52  2.2
Cells + IL-17 + NaB 83  1.3
Table 2.
Effects of IL-17 on cell growth, cell survival and caspase3 activity—IL-17 protects cells from butyrate-induced
apoptosis.
Treatment 24 hour; Relative Caspase 3
Activity (Fold)
48 hours Relative Caspase 3
Activity (Fold)
Cells alone 1.0 1.0
Cells + NaB 3.2  0.4 4.3  0.1
Cells + IL-17 + NaB 1.7  0.2 2.0  0.3
Table 3.
Effects of IL-17 on cell growth, cell survival and caspase3 activity—IL-17 inhibits butyrate-induced caspase3
activation. Data represent mean plus/minus SD.
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is already highly constitutively expressed in active from in these leukemia cells. This
could explain why IL-17 failed to stimulate NF-kB activation further in these cells.
3.5 Direct evidence that IL-17 activates PI-3 K/Akt signaling pathway in
leukemia cells
Because the PI-3 K inhibitor Ly20094 inhibited IL-17-induced cytokine expres-
sion, we examined the direct effects of IL-17 on PI-3 K and Akt phosphorylation and
activation. As shown in Figure 7a and 7b, in as early as 0.5 minutes, IL-17 stimu-
lated PI-3 K tyrosine phosphorylation by 4.5-fold. PI-3 K phosphorylation and
activation usually lead to downstream Akt (PKB) activation [113]. Therefore, we
next examined the effects of IL-17 on Akt (PKB) phosphorylation and activation.
Akt can be phosphorylated on Serine 473 (Ser473) and/or Threonine 308 (Thr308),
which is in the activation domain. The western blot results in Figure 8a show that
IL-17 stimulated Akt phosphorylation on Serine473 to 5-fold within 10 min in these
cells. The results in Figure 8b show that IL-17 stimulates rapid phosphorylation of
Akt on Thr308 with maximum effect noted at 5 minutes. Stimulation of Akt phos-
phorylation on Serine473 by IL-17 was inhibited by the PI-3 K inhibitor wortmannin
(WM) (no shown). These results imply that stimulation of Akt phosphorylation by
IL-17 is mediated by PI-3 K. Once Akt is activated, it phosphorylates a host of
downstream effectors including BAD, Caspase3, forkhead transcription factor
(FKHR), glycogen synthase kinase-3 (GSK3-beta), AFX, eNOS,TSC2, MDM2, P21/
CIP1 and other downstream effectors as shown in Figure 9a Dephosphorylated
BAD, caspase3 and GSK3-beta play vital roles in induction of apoptosis [114].
Figure 5.
Activation of STAT3 Transcriptional Activity by IL-17.
Figure 6.
Lack of IL-17 stimulation of NF-kB DNA Binding Activity.
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However, upon their phosphorylation, these pro-apoptotic proteins lose their pro-
apoptotic activities [114] as phosphorylation of both BAD, caspase3 and GSK-3
leads to their inactivation. The results in Figure 9b and c show that IL-17 stimulates
Akt-mediated BAD, Caspase3 and GSK-3-beta phosphorylation as p-BAD,
Figure 8.
Time course of IL-17 stimulation of AktSer473 phosphorylation (a) and (b) AktThr308 Specific antibody to either
AktSer473 or AktThr308 was used to monitor Akt phosphorylation by Western blot. Blots were stripped and
reprobed for total Akt for loading control. The blots from 3 experiments were scanned and results are presented.
Asterisk (*) indicates significant differences between IL-17 treated and untreated cells.
Figure 7.
Time course of IL-17-induced PI-3K phosphorylation detected by Western blot using either specific antibody for
tyrosine phosphorylated PI-3K or total PI-3K as loading control. Scanned values represent ptyr-PI-3K/PI-3K
ratios from 3 experiments (b). Asterisk (*) indicates significant differences between IL-17 treated and
untreated cells. Results are representation form several experiments.
Figure 9.
Model showing activated Akt phosphorylation of its downstream targets (a). Effect of IL-17 on Caspase3 and
BAD phosphorylation (b), GSK-3-beta phosphorylation (c). In (b) and (c) cells were untreated or stimulated
with IL-17 and total cell lysates were monitored for Caspase3, BAD and GSK-3-beta phosphorylation by
Western blot using specific phosphoprotein antibody to each protein. Total Akt (b) or total GSK-3-beta (c) was
probed for loading control. Results are representation of several experiments.
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p-Caspase3 and p-GSK3-beta were contained in Akt pulled down complex from
IL-17 treated cells. Phosphorylation of caspse3, BAD, GSK3-beta and STAT3 are
associated with enhanced cell survival [115, 116] and could explain in part how
IL-17 promotes cell survival. Also, IL-17 stimulated Akt-dependent phosphorylation
of mammalian target of rapamycin (mTor) on serine 2448 (motor Ser 2448) [117],
which was inhibited by the Akt inhibitor SH5 (not shown).
4. Discussions
We have provided strong evidence that IL-17 stimulates significance and differ-
ential expression of IL-2, IL-3, IL-10, IL-15, GRO, and RANTES in human leukemia
cells. The stimulatory effect of IL-17 on cytokine expression in these cells is similar
to previous reports in non-hematopoietic cells by IL-17 [16–20]. However, IL-17
does not stimulate IL-8 expression in these cells, which contradicts early reports
that IL-17-induces IL-8 expression in different cell types [17–20]. Induction of
cytokine expression by IL-17 in these leukemia cells could have strong biological
relevance in vivo because increases in IL-17 level in a tumor microenvironment can
trigger induction of other cytokines including chemokines that could generate
combination of proinflammatory, anti-inflammatory and chemotactic responses
[16–20, 54]; [79–81]. IL-2 is a proinflammatory cytokine [118], which also regulates
helper T cell differentiation [119]. IL-3 stimulates regulation of multipotent hema-
topoietic stem cell function and differentiation of all lineages as well as promote
proliferation of myeloid progenitor cells [120, 121]. IL-10 is a master regulator of
immunity to infection and an anti-inflammatory cytokine that can counteract the
pro-inflammatory effects of IL-2 [122]. Secondly, IL-10 is known to synergize with
IL-2 to promote CD8 + T cell cytotoxicity [123]. IL-15 is known to suppress apopto-
sis in T-lymphocytes by inducing Bcl2 and/or Bcl-xl in humans [124]. Perhaps, IL-
15 contributes to the anti-apoptotic effect of IL-17 in these cells. Both IL-2 and IL-15
have structural and functional similarities, share the common gamma chain of their
receptors and promote immune response [125]. Both GRO and RANTES are
chemokines and are associated with induction of chemotaxis and recruitment of
neutrophils and macrophages to sites of infection [37]. Thus, IL-17- induced GRO
and RANTES expression and secretion from leukemia cells into the culture media,
could account for the chemotactic effect IL-17 seen in our studies.
These leukemia cells express receptors for some of the cytokines secreted to the
culture media in response to IL-17. Therefore, some of the cytokines secreted into
culture media can promote both autocrine and paracrine effects on the leukemia
cells. We have provided evidence that IL-17 stimulates phosphorylation of the pro-
apoptotic proteins BAD, caspase3 and GSK3-beta, thus negating their functions. In
addition, IL-17 promotes inhibition of Caspase3 activity in these leukemia cells.
Furthermore, IL-17 enhances Akt phosphorylation and activation, which are asso-
ciated with cell survival [126]. The ability of IL-17 to enhance protection of the
leukemia cells from apoptosis implies that elevated IL-17 levels in a tumor micro-
environment could lead to promotion of leukemia cell proliferation and survival,
both of which could potentially produce poor prognosis in leukemia patients.
Another interesting outcome of this study is that IL-17 stimulates activation of
several transcriptional factors including cMyb, EGR-1, STAT3, Smad3/4, SRE, CDP,
which are known to regulate proliferation, differentiation and survival [115, 127,
128]. This effect of IL-17 could in part contribute to the mechanism growth promo-
tion and survival in these leukemia cells. Stimulation of smad3/4 transcriptional
factors of the TGF-beta signaling pathway [102, 115] by IL-17 may point to potential
cross talk between IL-17 and TGF-beta-induced signaling pathways to synergize
13
IL-17 Biological Effects and Signaling Mechanisms in Human Leukemia U937 Cells
DOI: http://dx.doi.org/10.5772/intechopen.96422
their biological effects [127, 128]. The lack of activation of NF-kB by IL-17 in these
leukemia cells is not surprising since typically these leukemia cells constitutively
express high levels of active NF-kB, which could explain the apparent lack of NF-kB
response to IL-17. Lack of NF-kB activation by IL-17 in these cells is in contrast to
IL-17-induced NF-kB activation reported in many cells [50].
We have provided ample evidence that IL-17 activates and utilizes the Jak/STAT
signaling pathway in these leukemia cells. In this pathway, IL-17 stimulates phos-
phorylation of Jak1, Jak2 and Jak3, STAT1, STAT2, and STAT3 [55, 93, 97]. We have
also shown that Jak2 partially mediates IL-17-induced IL-2 expression. Furthermore,
IL-17 strongly stimulates phosphorylation and activation of PI-3 K/ Akt pathway
and promoting Akt-mediated phosphorylation of its downstream effectors. Another
interesting observation is that Akt-partially mediates stimulation of IL-2 expression
and secretion by IL-17. Also, IL-17 promotes phospho-Akt’s association with BAD,
caspase3 and GSK3-beta, supporting Akt-mediated phosphorylation of these pro-
teins in IL-17 treated cells. These observations could in part explain how IL-17
promotes anti-apoptosis and survival in these leukemia cells [75–77, 126].
IL-17 stimulates activation of Raf–MEK–ERK1/2 pathway [92–95, 101], which
could partially account for the growth promoting effects of IL-17 in leukemia cells.
Previous thesis research in our laboratory revealed that IL-17 stimulates activation
of LCK [129] and PKC [130]. Also, IL-17 promotes association between LCK and the
p85 subunit of the PI-3 K, thus providing another mechanism for PI-3 K activation
by IL-17 via LCK, a member of the Src kinases family [129]. Activation of PKC by
IL-17 is associated with enhanced PKC ability to regulate cell cycle progression in
leukemia cells [130]. As indicated earlier, IL-17 is profoundly implicated in many
human diseases [55–74], thus supporting the suggestion that design and production
of anti-IL-17 drugs could lead to better strategies for development of new therapies
for those diseases [88–90]. Although the recent reports implicating IL-17 in the
mechanism of the “cytokine storm” event in COVID-19 infection is far from
Figure 10.
Model showing activated memory T cell secreted IL-17: Paracrine mechanism of how secreted IL-17 activates
cytokine expression and secretion in leukemia cells.
Figure 11.
Model showing multiple signaling mechanisms used by IL-17 in Leukemia Cells.
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conclusion, there are calls for development of anti-IL-17 drugs as adjunct therapy
for diseases in which IL-17 plays an active role [87, 131]. IL-17-enhanced leukemia
cell growth, survival and anti-apoptosis strengthens the argument in favor of inclu-
sion of leukemia in the list of human diseases for which anti-IL-17 adjunct therapy
should be considered. Our model in Figure 10 explains the paracrine role of T-cell
secreted IL-17 in leukemia cells. Elucidation of the multiple signaling mechanisms
of IL-17 in leukemia cells in our study and illustrated in Figure 11 further enrich our
knowledge on the biological effects and mechanisms of IL-17.
5. Conclusion
Our studies on effects and mechanisms of IL-17 in human U937 leukemia cells
revealed that these cells express IL-17A receptor and IL-17 stimulates cell growth,
survival, chemotaxis and differential expression of cytokines. These results suggest
that IL-17 could trigger expression and secretion of various cytokines including
chemotactic chemokines in leukemia patients. Also, IL-17 promotes anti-apoptotic
effects in these cells. If these biological effects of IL-17 described here, were to occur
in leukemia patients, IL-17 could promote poor prognosis in the patients. Further-
more, IL-17 stimulates differential activation of several transcriptional factors
including c-Myb, EGR-1, STAT3, smad3/4 CDP and SRE but not NF-kB in these
cells. Lastly, multiple signaling pathways including PI-3 K/Akt, Jak/STAT,
Raf–MEK-ERK-1/2 and Lck signaling pathways differentially mediate the biological
effects of IL-17 in the U937 leukemia cells. Any of these pathways could serve as a
target for anti-IL-17 drugs.
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